Press Releases

May 13, 2024
IN8bio Demonstrates Robust and Reproducible Gamma-Delta T Cell Therapy Manufacturing in Oral Presentation at ASGCT 2024
PDF Version
May 9, 2024
IN8bio Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
PDF Version
April 30, 2024
IN8bio Doses First Patient in Phase 2 Clinical Trial of INB-400 in Newly Diagnosed Glioblastoma
PDF Version
April 24, 2024
IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting
PDF Version
April 16, 2024
IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference
PDF Version